Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC

Submitted by Anonymous on

BackgroundOsimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However Abstract Background: Osimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell...

Usefulness OF SOX10 immunohistochemistry for subtyping diffuse midline gliomas EGFR-altered

Submitted by Anonymous on

Acknowledgements We would like to thank the laboratory technicians at the GHU Paris Neurosciences, Hospital Sainte-Anne, for their assistance. Authors thank Necker Imagine Tumor and DNA biobank (BB-033-00065). Funding DC and JG acknowledge funding from the charity “l’Etoile de Martin”...

A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications

Submitted by Anonymous on

Open AccessCase Report A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications by George DimitrovGeorge Dimitrov SciProfiles Scilit Preprints.org Google Scholar 1,2,*, Elitsa KraevskaElitsa Kraevska SciProfiles Scilit Preprints.org Google Scholar 2,3, Vladislav NankovVladislav Nankov...

Targeting pancreatic cancer with combined inhibition of EGFR and RAF

Submitted by Anonymous on

Abstract Pancreatic cancer is the third leading cause of cancer-related death, with a 5-year survival rate of only 10%. Preclinical studies remain essential for identifying novel therapeutic strategies, discovering biomarkers, and deepening the understanding of disease biology. The most frequent...

The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell Lung Cancer

Submitted by Anonymous on

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell...

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Submitted by Anonymous on

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17...

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches PR Newswire Wed, April 22, 2026 at...

Vitexin attenuates gastric precancerous lesions with EGFR as a potential target based on network pharmacology and molecular simulations

Submitted by Anonymous on

Precancerous gastric lesions (PLGC) represent a critical transitional stage toward gastric cancer, yet effective interventions to halt progression remain limited. Vitexin, a naturally occurring flavonoid, exhibits anti-cancer potential; however, its molecular targets and mechanisms in PLGC have not been fully...

Subscribe to Newsfeed